Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + bevacizumab + radiotherapy for advanced mucosal melanoma
ChiCTR2300078151Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab and bevacizumab in mucosal melanoma (MM), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: 6-month progression-free survival. Started Dec 2023; status: recruiting.
02
Drugs
adebrelimabbevacizumab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on ChiCTR2300078151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078151.